Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Mereo BioPharma Group (MREO) over the last 6 years, with Dec 2024 value amounting to -$0.06.

  • Mereo BioPharma Group's EPS (Weighted Average and Diluted) rose 50.00% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.06, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of -$0.06 for FY2024, which is 50.00% down from last year.
  • Per Mereo BioPharma Group's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.06 for FY2024, which was down 50.00% from -$0.04 recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's EPS (Weighted Average and Diluted) registered a high of -$0.04 during FY2023, and its lowest value of -$0.62 during FY2020.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.06, with a median of -$0.06 in 2024.
  • Per our database at Business Quant, Mereo BioPharma Group's EPS (Weighted Average and Diluted) surged by 89.07% in 2021 and then plummeted by 50.00% in 2024.
  • Over the past 5 years, Mereo BioPharma Group's EPS (Weighted Average and Diluted) (Yearly) stood at -$0.62 in 2020, then skyrocketed by 89.07% to -$0.07 in 2021, then dropped by 3.86% to -$0.07 in 2022, then soared by 42.86% to -$0.04 in 2023, then plummeted by 50.00% to -$0.06 in 2024.